BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20718420)

  • 1. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.
    Tsai TY; Yeh TK; Chen X; Hsu T; Jao YC; Huang CH; Song JS; Huang YC; Chien CH; Chiu JH; Yen SC; Tang HK; Chao YS; Jiaang WT
    J Med Chem; 2010 Sep; 53(18):6572-83. PubMed ID: 20718420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Tsu H; Chen X; Chen CT; Lee SJ; Chang CN; Kao KH; Coumar MS; Yeh YT; Chien CH; Wang HS; Lin KT; Chang YY; Wu SH; Chen YS; Lu IL; Wu SY; Tsai TY; Chen WC; Hsieh HP; Chao YS; Jiaang WT
    J Med Chem; 2006 Jan; 49(1):373-80. PubMed ID: 16392822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.
    Ryabtsova O; Jansen K; Van Goethem S; Joossens J; Cheng JD; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    Bioorg Med Chem Lett; 2012 May; 22(10):3412-7. PubMed ID: 22525314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
    Chen SJ; Jiaang WT
    Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors.
    Lu IL; Lee SJ; Tsu H; Wu SY; Kao KH; Chien CH; Chang YY; Chen YS; Cheng JH; Chang CN; Chen TW; Chang SP; Chen X; Jiaang WT
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3271-5. PubMed ID: 15927466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors.
    Van Goethem S; Van der Veken P; Dubois V; Soroka A; Lambeir AM; Chen X; Haemers A; Scharpé S; De Meester I; Augustyns K
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4159-62. PubMed ID: 18556198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).
    Jansen K; Heirbaut L; Verkerk R; Cheng JD; Joossens J; Cos P; Maes L; Lambeir AM; De Meester I; Augustyns K; Van der Veken P
    J Med Chem; 2014 Apr; 57(7):3053-74. PubMed ID: 24617858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.
    Van der Veken P; De Meester I; Dubois V; Soroka A; Van Goethem S; Maes MB; Brandt I; Lambeir AM; Chen X; Haemers A; Scharpé S; Augustyns K
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4154-8. PubMed ID: 18556199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Yeh TK; Tsai TY; Hsu T; Cheng JH; Chen X; Song JS; Shy HS; Chiou MC; Chien CH; Tseng YJ; Huang CY; Yeh KC; Huang YL; Huang CH; Huang YW; Wang MH; Tang HK; Chao YS; Chen CT; Jiaang WT
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3596-600. PubMed ID: 20483603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
    Lankas GR; Leiting B; Roy RS; Eiermann GJ; Beconi MG; Biftu T; Chan CC; Edmondson S; Feeney WP; He H; Ippolito DE; Kim D; Lyons KA; Ok HO; Patel RA; Petrov AN; Pryor KA; Qian X; Reigle L; Woods A; Wu JK; Zaller D; Zhang X; Zhu L; Weber AE; Thornberry NA
    Diabetes; 2005 Oct; 54(10):2988-94. PubMed ID: 16186403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?
    Van Goethem S; Matheeussen V; Joossens J; Lambeir AM; Chen X; De Meester I; Haemers A; Augustyns K; Van der Veken P
    J Med Chem; 2011 Aug; 54(16):5737-46. PubMed ID: 21711053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
    Stremenová J; Mares V; Lisá V; Hilser M; Krepela E; Vanicková Z; Syrucek M; Soula O; Sedo A
    Int J Oncol; 2010 Feb; 36(2):351-8. PubMed ID: 20043068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and SAR of potent and selective dipeptide-derived inhibitors for dipeptidyl peptidases.
    Senten K; Van der Veken P; De Meester I; Lambeir AM; Scharpé S; Haemers A; Augustyns K
    J Med Chem; 2003 Nov; 46(23):5005-14. PubMed ID: 14584950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.
    Meadows SA; Edosada CY; Mayeda M; Tran T; Quan C; Raab H; Wiesmann C; Wolf BB
    Biochemistry; 2007 Apr; 46(15):4598-605. PubMed ID: 17381073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase 8/9-like activity in human leukocytes.
    Maes MB; Dubois V; Brandt I; Lambeir AM; Van der Veken P; Augustyns K; Cheng JD; Chen X; Scharpé S; De Meester I
    J Leukoc Biol; 2007 May; 81(5):1252-7. PubMed ID: 17287297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors.
    Tsai TY; Coumar MS; Hsu T; Hsieh HP; Chien CH; Chen CT; Chang CN; Lo YK; Wu SH; Huang CY; Huang YW; Wang MH; Wu HY; Lee HJ; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3268-72. PubMed ID: 16581245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors.
    Kang NS; Ahn JH; Kim SS; Chae CH; Yoo SE
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3716-21. PubMed ID: 17462890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Yeh TK; Chen X; Huang CY; Chang CN; Yeh KC; Hsieh SH; Chien CH; Chang YW; Huang CH; Huang YW; Huang CL; Wu SH; Wang MH; Lu CT; Chao YS; Jiaang WT
    Bioorg Med Chem; 2009 Mar; 17(6):2388-99. PubMed ID: 19261480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
    Yazbeck R; Howarth GS; Abbott CA
    Trends Pharmacol Sci; 2009 Nov; 30(11):600-7. PubMed ID: 19837468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.